AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide

AbbVie Inc.

2025-Q2 EPS reported $1.24 vs consensus $2.94 ▼ miss (-57.9%)

Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.
Full-year 2025 adjusted diluted EPS guidance range lowered to $11.67-$11.87 from $12.09-$12.29.
Q2 2025 adjusted diluted EPS guidance range now $2.84-$2.88 versus prior $3.26-$3.30.
Guidance excludes any acquired IPR&D expense beyond Q2 2025 due to forecasting uncertainty.
Q2 2025 results are preliminary and subject to financial statement closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.